These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 29408938)

  • 1. Cost-effectiveness of liraglutide versus lixisenatide as add-on therapies to basal insulin in type 2 diabetes.
    Ericsson Å; Glah D; Lorenzi M; Jansen JP; Fridhammar A
    PLoS One; 2018; 13(2):e0191953. PubMed ID: 29408938
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost Effectiveness of Insulin Degludec Plus Liraglutide (IDegLira) in a Fixed Combination for Uncontrolled Type 2 Diabetes Mellitus in Sweden.
    Ericsson Å; Lundqvist A
    Appl Health Econ Health Policy; 2017 Apr; 15(2):237-248. PubMed ID: 28063135
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term Cost-effectiveness of Two GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus in the Italian Setting: Liraglutide Versus Lixisenatide.
    Hunt B; Kragh N; McConnachie CC; Valentine WJ; Rossi MC; Montagnoli R
    Clin Ther; 2017 Jul; 39(7):1347-1359. PubMed ID: 28625506
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the long-term cost-effectiveness of IDegLira versus liraglutide added to basal insulin for patients with type 2 diabetes failing to achieve glycemic control on basal insulin in the USA.
    Hunt B; Mocarski M; Valentine WJ; Langer J
    J Med Econ; 2017 Jul; 20(7):663-670. PubMed ID: 28294641
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness analysis of exenatide once-weekly versus dulaglutide, liraglutide, and lixisenatide for the treatment of type 2 diabetes mellitus: an analysis from the UK NHS perspective.
    Chuang LH; Verheggen BG; Charokopou M; Gibson D; Grandy S; Kartman B
    J Med Econ; 2016 Dec; 19(12):1127-1134. PubMed ID: 27310712
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost Effectiveness of IDegLira vs. Alternative Basal Insulin Intensification Therapies in Patients with Type 2 Diabetes Mellitus Uncontrolled on Basal Insulin in a UK Setting.
    Davies MJ; Glah D; Chubb B; Konidaris G; McEwan P
    Pharmacoeconomics; 2016 Sep; 34(9):953-66. PubMed ID: 27438706
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluating the long-term cost-effectiveness of fixed-ratio combination insulin degludec/liraglutide (IDegLira) for type 2 diabetes in Spain based on real-world clinical evidence.
    Raya PM; Blasco FJA; Hunt B; Martin V; Thorsted BL; Basse A; Price H
    Diabetes Obes Metab; 2019 Jun; 21(6):1349-1356. PubMed ID: 30740861
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluating the short-term cost-effectiveness of liraglutide versus lixisenatide in patients with type 2 diabetes in the United States.
    Hunt B; McConnachie CC; Gamble C; Dang-Tan T
    J Med Econ; 2017 Nov; 20(11):1117-1120. PubMed ID: 28651479
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The management of type 2 diabetes with fixed-ratio combination insulin degludec/liraglutide (IDegLira) versus basal-bolus therapy (insulin glargine U100 plus insulin aspart): A short-term cost-effectiveness analysis in the UK setting.
    Drummond R; Malkin S; Du Preez M; Lee XY; Hunt B
    Diabetes Obes Metab; 2018 Oct; 20(10):2371-2378. PubMed ID: 29797389
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treating Patients with Type 2 Diabetes Mellitus Uncontrolled on Basal Insulin in the Czech Republic: Cost-Effectiveness of IDegLira Versus iGlarLixi.
    Pöhlmann J; Russel-Szymczyk M; Holík P; Rychna K; Hunt B
    Diabetes Ther; 2019 Apr; 10(2):493-508. PubMed ID: 30706364
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the long-term cost-effectiveness of liraglutide vs lixisenatide for treatment of type 2 diabetes mellitus in the UK setting.
    Hunt B; Vega-Hernandez G; Valentine WJ; Kragh N
    Diabetes Obes Metab; 2017 Jun; 19(6):842-849. PubMed ID: 28124820
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ideglira is Associated With Improved Short-Term Clinical Outcomes and Cost Savings Compared with Insulin Glargine U100 Plus Insulin Aspart in the U.S.
    Dempsey M; Mocarski M; Langer J; Hunt B
    Endocr Pract; 2018 Sep; 24(9):796-804. PubMed ID: 30308134
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of once daily GLP-1 receptor agonist lixisenatide compared to bolus insulin both in combination with basal insulin for the treatment of patients with type 2 diabetes in Norway.
    Huetson P; Palmer JL; Levorsen A; Fournier M; Germe M; McLeod E
    J Med Econ; 2015; 18(8):573-85. PubMed ID: 25853868
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of once-weekly semaglutide versus dulaglutide and lixisenatide in patients with type 2 diabetes with inadequate glycemic control in Sweden.
    Ericsson Å; Fridhammar A
    J Med Econ; 2019 Oct; 22(10):997-1005. PubMed ID: 31044636
    [No Abstract]   [Full Text] [Related]  

  • 15. The short-term cost-effectiveness of once-daily liraglutide versus once-weekly exenatide for the treatment of type 2 diabetes mellitus in the United States.
    Wang B; Roth JA; Nguyen H; Felber E; Furnback W; Garrison LP
    PLoS One; 2015; 10(4):e0121915. PubMed ID: 25849542
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of lixisenatide in combination with basal insulin vs other insulin regimens for the treatment of patients with type 2 diabetes inadequately controlled by basal insulin: Systematic review, network meta-analysis and cost-effectiveness analysis.
    Men P; Qu S; Luo W; Li C; Zhai S
    Diabetes Obes Metab; 2020 Jan; 22(1):107-115. PubMed ID: 31469217
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost Effectiveness of Exenatide Once Weekly Versus Insulin Glargine and Liraglutide for the Treatment of Type 2 Diabetes Mellitus in Greece.
    Tzanetakos C; Bargiota A; Kourlaba G; Gourzoulidis G; Maniadakis N
    Clin Drug Investig; 2018 Jan; 38(1):67-77. PubMed ID: 29080210
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of add-on treatments to metformin in a Swedish setting: liraglutide vs sulphonylurea or sitagplitin.
    Steen Carlsson K; Persson U
    J Med Econ; 2014 Sep; 17(9):658-69. PubMed ID: 24950434
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IDegLira Improves Both Fasting and Postprandial Glucose Control as Demonstrated Using Continuous Glucose Monitoring and a Standardized Meal Test.
    Holst JJ; Buse JB; Rodbard HW; Linjawi S; Woo VC; Boesgaard TW; Kvist K; Gough SC
    J Diabetes Sci Technol; 2015 Oct; 10(2):389-97. PubMed ID: 26443290
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-Effectiveness of iGlarLixi in People with Type 2 Diabetes Mellitus Suboptimally Controlled on Basal Insulin Plus Metformin in the UK.
    McCrimmon RJ; Falla E; Sha JZ; Alsaleh AJO; Lew E; Hudson R; Baxter M; Palmer K
    Diabetes Ther; 2021 Dec; 12(12):3217-3230. PubMed ID: 34714523
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.